Skip to main content Skip to footer
American Family Children's Hospital
Mark E. Burkard, MD, PhD close
Mark E. Burkard, MD, PhD

New Patients

Need help selecting a primary care doctor? Contact the Welcome Center for personal assistance.

For Referring Physicians

How to refer a patient

Mark E. Burkard, MD, PhD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Mark Burkard is an assistant professor of medicine in the Hematology-Oncology section of the UW School of Medicine and Public Health and is a member of the UW Health Breast Center. Dr. Burkard received his medical degree and PhD in chemistry from the University of Rochester. He subsequently trained in internal medicine at New York Hospital-Cornell University and in medical oncology at Memorial Sloan-Kettering Cancer Center. During his oncology fellowship, he studied cell cycle enzymes as novel targets for cancer therapy. He is board certified in Internal Medicine and Medical Oncology. As an oncologist, his clinical practice and research interest is in breast cancer and experimental therapeutics.


Medical Oncology

Breast Cancer


UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 266-6400 | (800) 323-8942 | Map
University Hospital
(608) 266-6400 | (800) 323-8942 | Map

Hospital Affiliation(s)

University Hospital
Veterans Hospital - Wm. S. Middleton Memorial

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Medical Oncology
Fellowship Memorial Sloan-Kettering Cancer Center, New York, NY
Medical School University of Rochester School of Medicine, Rochester, NY

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

Dr. Burkard is interested in targeted therapy directed at protein kinases. His laboratory seeks to link therapies with their targets within cancer cells using genetic tools, and to identify patients whose cancers are most likely to benefit from particular drugs. These studies will be used to inform clinical development of novel agents. Dr. Burkard is part of the breast cancer disease oriented working group.

PubMed Articles
Denu RA Shabbir M Nihal M Singh CK Longley BJ Burkard ME Ahmad N Centriole Overduplication is the Predominant Mechanism Leading to Centrosome Amplification in Melanoma. Mol Cancer Res . 2018 Mar;16(3):517-527
[PubMed ID: 29330283]
Shah RA Bennett DD Burkard ME Photosensitive lichenoid skin reaction to capecitabine. BMC Cancer . 2017 Dec 19;17(1):866
[PubMed ID: 29258457]
Ma CX Suman V Goetz MP Northfelt D Burkard ME Ademuyiwa F Naughton M Margenthaler J Aft R Gray R Tevaarwerk A Wilke L Haddad T Moynihan T Loprinzi C Hieken T Barnell EK Skidmore ZL Feng YY Krysiak K Hoog J Guo Z Nehring L Wisinski KB Mardis E Hagemann IS Vij K Sanati S Al-Kateb H Griffith OL Griffith M Doyle L Erlichman C Ellis MJ A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast Cancer. Clin Cancer Res . 2017 Nov 15;23(22):6823-6832
[PubMed ID: 28874413]
Wu CG Chen H Guo F Yadav VK Mcilwain SJ Rowse M Choudhary A Lin Z Li Y Gu T Zheng A Xu Q Lee W Resch E Johnson B Day J Ge Y Ong IM Burkard ME Ivarsson Y Xing Y PP2A-B' holoenzyme substrate recognition, regulation and role in cytokinesis. Cell Discov . 2017;3:17027
[PubMed ID: 28884018]
Denu RA Burkard ME Synchronous Bilateral Breast Cancer in a Patient With Nager Syndrome. Clin Breast Cancer . 2017 Jun;17(3):e151-e153
[PubMed ID: 28139434]
Tevaarwerk AJ Hocking WG Zeal JL Gribble M Seaborne L Buhr KA Wisinski KB Burkard ME Wiegmann DA Sesto ME Accuracy and Thoroughness of Treatment Summaries Provided as Part of Survivorship Care Plans Prepared by Two Cancer Centers. J Oncol Pract . 2017 May;13(5):e486-e495
[PubMed ID: 28221896]
Burkard ME Deming DA Lauring J Using cancer genomics to guide clinical decisions. Cancer . 2017 Apr 15;123(8):1288-1291
[PubMed ID: 28253425]
Burkard ME Weaver BA Tuning Chromosomal Instability to Optimize Tumor Fitness. Cancer Discov . 2017 Feb;7(2):134-136
[PubMed ID: 28167614]
Rampurwala M Wisinski KB Burkard ME Ehsani S O'Regan RM Carmichael L Kim K Kolesar J Tevaarwerk AJ Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer. Invest New Drugs . 2017 Feb;35(1):87-94
[PubMed ID: 27826831]
Kim H Johnson JM Lera RF Brahma S Burkard ME Anillin Phosphorylation Controls Timely Membrane Association and Successful Cytokinesis. PLoS Genet . 2017 Jan;13(1):e1006511
[PubMed ID: 28081137]
Wisinski KB Xu W Tevaarwerk AJ Saha S Kim K Traynor A Dietrich L Hegeman R Patel D Blank J Harter J Burkard ME Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study. Clin Breast Cancer . 2016 Aug;16(4):256-61
[PubMed ID: 27133732]
Wisinski KB Tevaarwerk AJ Burkard ME Rampurwala M Eickhoff J Bell MC Kolesar JM Flynn C Liu G Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. Clin Cancer Res . 2016 Jun 1;22(11):2659-67
[PubMed ID: 27026198]
Lera RF Potts GK Suzuki A Johnson JM Salmon ED Coon JJ Burkard ME Decoding Polo-like kinase 1 signaling along the kinetochore-centromere axis. Nat Chem Biol . 2016 Jun;12(6):411-8
[PubMed ID: 27043190]
Lasek AL McPherson BM Trueman NG Burkard ME The Functional Significance of Posttranslational Modifications on Polo-Like Kinase 1 Revealed by Chemical Genetic Complementation. PLoS One . 2016;11(2):e0150225
[PubMed ID: 26919439]
Denu RA Zasadil LM Kanugh C Laffin J Weaver BA Burkard ME Centrosome amplification induces high grade features and is prognostic of worse outcomes in breast cancer. BMC Cancer . 2016 Jan 29;16:47
[PubMed ID: 26832928]
Choudhary A Zachek B Lera RF Zasadil LM Lasek A Denu RA Kim H Kanugh C Laffin JJ Harter JM Wisinski KB Saha S Weaver BA Burkard ME Identification of Selective Lead Compounds for Treatment of High-Ploidy Breast Cancer. Mol Cancer Ther . 2016 Jan;15(1):48-59
[PubMed ID: 26586723]
Rampurwala MM Rocque GB Burkard ME Update on adjuvant chemotherapy for early breast cancer. Breast Cancer (Auckl) . 2014;8:125-33
[PubMed ID: 25336961]
Burkard ME Wisinski KB Njiaju UO Donohue S Hegeman R Stella A Mansky P Shah V Goggins T Qamar R Dietrich L Kim K Traynor AM Tevaarwerk AJ Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study. Clin Breast Cancer . 2014 Jun;14(3):205-11
[PubMed ID: 24342730]
Robins HI Burkard ME Halberg RB "TRIMing" the patient population to increase the benefit of mTOR inhibition. J Natl Cancer Inst . 2014 Apr 28;106(5)
[PubMed ID: 24777109]
Zasadil LM Andersen KA Yeum D Rocque GB Wilke LG Tevaarwerk AJ Raines RT Burkard ME Weaver BA Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles. Sci Transl Med . 2014 Mar 26;6(229):229ra43
[PubMed ID: 24670687]